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Machine Learning and Glioma Imaging Biomarkers 
Background: Increased computational processing power and advances in database curation will 
facilitate the development of biomarkers that may contribute to the defeat of cancer in the mid-21st-
century.  
Aim: We review how machine learning is applied to imaging biomarkers in neuro-oncology, in 
particular for diagnosis, prognosis and treatment response monitoring.  
Methods: The PubMed and MEDLINE databases were searched for articles published before 
September 2018 using relevant search terms. The search strategy focused on articles applying ML 
to high grade glioma biomarkers for treatment response monitoring, prognosis and prediction. 
Results: Magnetic resonance imaging is typically used throughout the patient pathway because 
routine structural imaging provides detailed anatomical and pathological information and advanced 
techniques provide additional physiological detail. Using carefully chosen image features, machine 
learning is frequently used to allow accurate classification in a variety of scenarios. Rather than 
being chosen by human selection, machine learning also enables image features to be identified by 
an algorithm. Much research is applied to determining molecular profiles, histological tumour grade 
and prognosis using magnetic resonance images acquired at the time that patients first present with 
a brain tumour. Differentiating a treatment response from a post-treatment related effect using 
imaging is clinically important and also an area of active study (described here in one of two Special 
Issue publications dedicated to the application of machine learning in glioma imaging).  
Conclusion: Whilst pioneering, most of the evidence is of a low level having been obtained 
retrospectively and in single centres. Studies applying machine learning to build neuro-oncology 
monitoring biomarker models have yet to show overall advantage over those using traditional 
statistical methods. Development and validation of machine learning models applied to neuro-
oncology require large, well-annotated datasets, and therefore multidisciplinary and multi-centre 
collaborations are necessary. 
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Introduction 
A biomarker, a portmanteau of biological and marker, is defined as a characteristic that is measured as an indicator 
of normal biological processes, pathogenic processes, or responses to a therapeutic intervention1. Molecular, 
histologic, imaging, or physiologic characteristics are types of biomarkers. Well-known biomarkers in neuro-
oncology include demographic features (such as age) and tumour features (such as grade and O6-methylguanine-
DNA methyltransferase (MGMT) promoter methylation status), while imaging biomarkers are used for diagnosis, 
prognosis and treatment response monitoring. 
MRI is typically used throughout the neuro-oncology patient pathway because routine structural imaging provides 
detailed anatomical and pathological information, and advanced techniques (such as 1H-magnetic resonance 
spectroscopy) provide additional physiological detail2. Qualitative analysis of a new intracranial mass aids 
diagnosis and in routine clinical practice can determine whether or not to proceed to confirmatory biopsy or 
resection. For example, with some basic demographic information such as the age of the patient and with some 
clinical information, such as knowledge that the mass was found incidentally whilst investigating an unrelated 
condition, the qualitative routine structural imaging features of a grade 1 meningioma allow diagnosis with high 
precision (positive predictive value) without the need for confirmatory biopsy. Advanced imaging techniques 
allow quantitative analysis of abnormalities that can change management. For example, cerebral blood volume 
values obtained using dynamic susceptibility-weighted contrast-enhanced imaging (DSC) imaging within an area 
of tumour contrast enhancement, or 1H-magnetic resonance spectroscopic ratios acquired from a mass, may help 
determine whether a tumour is of high histological grade (grade 3 or 4) in certain scenarios.  
Some image analysis recommendations, which determine treatment response of high histological grade gliomas 
(Box 1), have become common in the research setting and rely on simple linear metrics of image features, namely 
the product of the maximal perpendicular cross-sectional dimensions of contrast enhancing tumour (in 
“measurable” lesions which are defined as beyond 10 mm in all perpendicular dimensions)3,4. Nonetheless, 
seemingly simple measurements can still be challenging because tumours have a variety of shapes, may be 
confined to a cavity rim, and the edge may be difficult to define. Indeed, large, cyst-like high grade gliomas are 
common and are often “non-measurable” unless a solid peripheral nodular component fulfils the above 
“measurable” criteria.  
 
 
Box 1. Neuro-oncology epidemiology 
The global incidence of CNS tumours is unknown but is at least 45/100 000 patients a year5,6. CNS tumours 
are categorised as primary or secondary. Secondary CNS tumours (metastases) are the commonest type of CNS 
tumour in adults. The reported incidence of metastatic CNS tumours is increasing but the exact incidence is 
unknown. Primary CNS tumours are diverse histological entities with different causes and include malignant, 
benign and borderline tumours. The 2016 World Health Organization classification of primary CNS tumours 
is based on histopathological and molecular criteria7. In the USA, the incidence of primary CNS tumours is 
21/100,000 patients a year8. The two main histological types are meningiomas and gliomas accounting for 36% 
and 28% of primary CNS tumours respectively.  
 
There are 4 histological glioma grades. Grade 4 gliomas (glioblastoma) are the commonest glioma (53%)9. 
Diffuse grade 2 (diffuse low-grade) and 3 (anaplastic) gliomas account for approximately 30% of all gliomas. 
The median age at diagnosis of these gliomas are 64, 43 and 56 years respectively. In contrast, the commonest 
paediatric gliomas are grade 1 (predominantly pilocytic astrocytomas) accounting for 33% of paediatric 
gliomas10. Almost all machine learning studies applied to neuro-oncology have focused on gliomas, particularly 
high grade gliomas (grades 3 and 4) which are the malignant gliomas. 
 
Much research in image analysis aims to extract underlying quantitative information from the imaging dataset to 
develop biomarkers that may not be readily visible to individual human raters; this is radiomics. Typically, 
radiomics consists of the following phases: pre-processing images, feature estimation (quantifying or 
characterizing the image), feature selection (dimensionality reduction to remove noise and random error in the 
underlying data and therefore reduce overfitting), classification (decision or discriminant analysis) and 
evaluation11 (Fig. 1).  Pre-processing typically constitutes a major part of most studies. Although many steps can 
be taken prior to patient imaging to reduce the pre-processing burden (e.g. overcoming geometric distortion 
through phantom analysis or reduce image noise through signal averaging), typically images will require intensity 
non-uniformity correction (through estimation of bias field), noise reduction (through careful application of 
filters), motion correction, and intensity normalization (through transformation of intensity to standard scale), and 
often spatial normalization (different brains anatomically aligned through geometrical transformation), and 
segmentation. Pre-processing pipelines are complex but potentially can have empirical, data-driven, and complete 
machine learning solutions to the problems described above13, including quantification of the inherent 
uncertainty14.  
 
Some research has leveraged applied statistical models, some machine learning (ML) models and many both. The 
basic difference between them is that statistics draws population inferences from a sample, and ML finds 
generalizable predictive patterns15. Some of the recent shifts towards ML can be attributable, firstly, to ML 
methods being effective when applied to 'wide data', where the number of input variables exceeds the number 
of subjects; and secondly, to applied statistical modeling being inherently designed for data with tens of input 
variables and sample sizes smaller than those seen with current data curation (big data). Together, these 
explain some of the recent shifts towards ML. In this review we focus on ML approaches to neuro-oncology 
radiomics (Box 2).  
 
Box 2. Assessing machine learning methodology in neuro-oncology radiomic studies 
One of the challenges when interpreting the literature on machine learning (ML) approaches to neuro-oncology 
is that different researchers may use different technologies as the basis for their work. As a result, the reader 
can face technical details that may appear challenging. In fact, many techniques share similar underlying 
motivations, and even when they do not, there are some basic principles that apply to assessing ML 
applications. Firstly, because ML models tend to start with the data and then generalise, overfitting is a 
substantial challenge. For this reason, model validation on dual training and testing datasets is recommended. 
Secondly, common, simple clinical data incorporation or comparison is likely to be important. Thirdly, 
assessing performance against an existing standard (typically an existing assessment system or human expert 
performance) is essential. 
 
There has been a long history of using ML in neuro-oncology, and even neural networks have been applied to 
classifier tasks for more than two decades16. However, recent work has made use of improvements in technology 
to allow the use of much more complex supervised, unsupervised and reinforcement ML including the use of deep 
(multiple layered) neural networks (some relevant open source tools are listed in Supplementary Box 1). 
Nonetheless, for now, most radiomic work uses explicit rather than implicit feature engineering techniques (i.e. 
features chosen by imaging scientists such as texture17, rather than features identified by an algorithm). 
 
Evaluation in image analysis research initially consists of analytical validation, where accuracy and reliability of 
the biomarker are assessed18. Accuracy determines how often a test is correct in a given population (the number 
of true positives and true negatives divided by the number of overall tests). Accuracy alone is limited and other 
metrics derived from the confusion matrix are typically employed such as precision (positive prediction value), 
recall (sensitivity), the F1 score (recall and precision combined), balanced accuracy (the mean of sensitivity and 
specificity) and area under the receiver operator curve (AUC). Clinical validation is the testing of biomarker 
performance, typically in a clinical trial. One weakness of much current work is that novel approaches are 
validated against existing biomarkers. For example, an attempt to validate a new DSC imaging biomarker for 
treatment response monitoring may involve benchmarking it against a common biomarker for treatment response, 
such as the product of the maximal perpendicular cross-sectional dimensions of contrast enhancing tumour, rather 
than overall survival. However, the common biomarker itself may not be rigorously proven to be clinically valid. 
Indeed, when the maximal perpendicular cross-sectional dimensions of contrast enhancing tumour have been used 
to determine progression-free survival in high grade glioma, there may be false positive progression 
(pseudoprogression described below) or, when bevacuzimab is added to the treatment regimen, false negative 
progression (pseudoresponse). Even expert recommendations4 for avoiding false positive progression through 
careful timing of cross-sectional measurements are flawed, requiring modifications12. False negative progression 
is a concern in the United States but rarely in Europe as the European Medicines Agency concluded that the 
progression-free survival bevacuzimab trial outcome measures were inherently confounded and the use of 
bevacuzimab is not supported19. 
 This review describes several illustrative radiomic studies aimed at developing imaging biomarkers for treatment 
response monitoring, prognosis and prediction as well as diagnosis (outlined in the adjoining publication: Deep 
learning can see the unseeable: predicting molecular markers from MRI of brain gliomas). We demonstrate how 
different ML strategies are used in classification in particular, as well as in feature estimation and selection. As is 
fundamental to biomarker development, the extent of analytical and clinical validation is highlighted. The studies 
described here, many of which are retrospective and performed in single centres, show that while there is 
considerable research on applying ML to neuro-oncology, the evidence is often poor thereby limiting clinical 
utility and deployment20.  
 
Material and Methods 
The PubMed and MEDLINE databases were searched for articles published between September 2008 and 2018 
(reviews) and September 2013 and 2018 (original research) using the search terms listed in Supplementary Table 
1 based on variants of glioma and machine learning search term combinations. We excluded those articles where 
there was no mention of a machine learning algorithm used in feature extraction, selection or 
classification/regression. We excluded all articles which were not in the English language or did not have an 
obtainable English language translation. We excluded all articles which had no mention of imaging in the abstract 
or title. 
 
Given that our review describes a broad range of studies involving several imaging approaches (a range of MRI 
sequences including structural and advanced techniques; also PET) and several target conditions 
(pseudoprogression, radiation necrosis, or a combination of both; complete response) it is not suitable for a 
PRISMA-DTA analysis addressing a specific question on diagnostic accuracy21. Nonetheless, components of the 
PRISMA-DTA methodology have been incorporated where practicable. 
Results 
The search strategy returned 1549 initial candidate articles. Following our exclusion steps (Supplementary Figure 
1) the final dataset consisted of 20 studies primarily assessing prognostic biomarkers and 14 studies primarily 
assessing monitoring biomarkers.  
Monitoring Biomarkers 
Monitoring biomarkers are measured serially and may detect change in extent of disease, provide evidence of 
treatment exposure or assess safety1. There is an overlap with safety biomarkers which specifically determine any 
treatment toxicity. Monitoring blood or cerebral spinal fluid for circulating tumour cells, exosomes, and 
microRNAs shows promise18. However, imaging is particularly useful as it is non-invasive and captures the entire 
tumour volume and adjacent tissues and has led to recommendations to determine treatment response in trials3,4. 
Clinical validation is typically not proven. Common biomarkers are frequently used as benchmarks in an attempt 
to indirectly validate the monitoring biomarker under development. 
The commonest primary malignant brain tumour, glioblastoma, is a devastating disease with a progression free-
survival of 15% at 1 year and a median overall survival of 14.6 months despite standard of care treatment22,23. The 
standard of care treatment consists of maximal debulking surgery and radiotherapy, with concomitant and 
adjuvant temozolomide22, but is associated with pseudoprogression. This describes false-positive progressive 
disease within 6 months of chemoradiotherapy, typically determined by changes in contrast enhancement on T1-
weighted MR images, representing non-specific blood-brain barrier disruption24,25 (Fig. 2). Pseudoprogression 
confounds response assessment and may affect clinical management. It occurs in 20-30% of cases and is 
associated with better clinical outcomes26. Apparent tumour progression on MRI, therefore, commonly presents 
the neuro-oncologist with the difficult decision as to whether to continue adjuvant temozolomide or not. An 
imaging technique that reliably differentiates patients with true progression from those with pseudoprogression 
would allow an early change in treatment strategy with cessation of ineffective treatment and the option of 
implementing second line therapies27. This is an area of significant potential impact: only 50% of patients with 
glioblastoma receive second-line treatment, even in clinical trials. 
Pseudoprogression is an early-delayed treatment effect, in contrast to the late-delayed radiation effect (or radiation 
necrosis)28. Whereas pseudoprogression occurs during or within 6 months of chemoradiotherapy, radiation 
necrosis occurs after this period but at an incidence that is an order of magnitude smaller than the earlier 
pseudoprogression. In the same way that it would be beneficial to have an imaging technique that discriminates 
true progression from pseudoprogression, an imaging technique that discriminates true progression from radiation 
necrosis would also be beneficial to allow the neuro-oncologist to know whether to implement second line 
therapies or not. 
For these reasons, multiple radiomic studies have attempted to develop monitoring biomarkers and ML has been 
central to the method (Table 1). We describe several of these studies below in order to demonstrate a range of ML 
techniques which incorporate different imaging approaches (e.g. different sequences and combinations of 
sequences) and serve as examples containing methodological strengths and weaknesses. Other monitoring 
biomarkers have been developed for other reasons including surveillance imaging of low grade gliomas which 
will invariably transform to a high grade glioma29.  
Going solo: a single imaging type can be used to analyse pseudoprogression 
 
In the first example, the study aim was to use an ML algorithm to differentiate progression from 
pseudoprogression in glioblastoma at the earliest time point when an enlarging contrast-enhancing lesion is seen 
within 6 months following chemoradiation completion, using T2-weighted images alone12. Unsupervised feature 
estimation was performed to investigate topological descriptors of image heterogeneity (Minkowski functionals). 
Confounders were determined using principal component analysis and they showed that simple clinical features 
(e.g. Karnofsky performance status), were not discriminatory. Feature selection reduced the number of features 
to consider from 32 to 7. Supervised analysis with a support vector machine (SVM) and leave-one-out cross 
validation (LOOCV) gave an accuracy of 0.88 and AUC of 0.9 in a retrospective training dataset of 17 patients 
and the model gave 0.86 accuracy in a prospective test dataset of 7 patients with 100% recall and 80% precision. 
Although not apparent to the reporting radiologist, the T2-weighted hyperintensity phenotype of those patients 
with progression was heterogeneous, large and frond-like when compared to those with pseudoprogression. The 
pseudoprogression phenotype on T2-weighted images was shown to be a distinct entity and different from 
vasogenic oedema and radiation necrosis. 
 
Additional analytical validation was performed firstly in the form of reliability testing which showed that a 
different operator performing segmentation achieved 100% classification concordance. Secondly, the same results 
using a different software package and a different operator were also obtained. Thirdly, a different feature 
selection method (random forest) and classifier (least absolute shrinkage and selection operator; LASSO) were 
used and also gave the same evaluation values with 6 similar selected features.  
A strength of the study is that T2-weighted images alone were used increasing the chance of translation to the 
clinic. However, the study was small and performed in a single centre and the biomarker requires clinical 
validation in a larger multicentre test dataset (open access code was provided for others to study this). 
In another study, the aim was also to use an ML algorithm to differentiate progression from pseudoprogression at 
the earliest time point when an enlarging contrast-enhancing lesion is seen, using [18F]-fluoroethyl-L-tyrosine 
(FET) positron emission tomography30. The small, single centre, proof-of-concept study which included all high 
grade gliomas, showed that ML could be applied to imaging modalities other than MRI. First and second order 
statistics were obtained from the images of 14 patients and underwent unsupervised consensus clustering. The 
cumulative distribution function was used to determine the optimal class size. Feature selection by predictive 
analysis of microarrays methodology using 10-fold cross validation reduced the features from 19 to 10. Three 
class PET-based clusters were derived and progression and pseudoprogression could be differentiated with 90% 
recall and precision. However, there was no test dataset and the performance was similar to standard PET analysis 
using the maximal tracer uptake in the tumour divided by that in normally appearing brain tissue. This study 
highlights some of the challenges with such studies: the sample size is small, and there is no clear proof that the 
new approach is better than existing ones. 
Another glioblastoma study aimed to differentiate progression from pseudoprogression at the earliest time point 
when an enlarging contrast-enhancing lesion is seen, using post-contrast T1-weighted images alone31. They 
constructed a convolutional neural network (CNN) using data from 59 patients and tested its performance in 19 
patients. The model performed better when combined with clinical parameters than without, giving an AUC of 
0.83, area under the precision-recall curve (AUPRC) of 0.87, and F1-score of 0.74. As is the case with much 
CNN-based work, they were unable to determine what features were important among the input data. The optimal 
CNN model also performed better than a random forest model with clinical parameters alone, although it is worth 
noting that performance status was not included32. The strengths were that the testing dataset came from a second 
hospital and that it used post-contrast T1-weighted images alone, which makes the approach potentially more 
applicable. Again, open access code is provided. 
In summary, the three studies above demonstrate that a range of ML techniques can be used to differentiate 
progression and pseudoprogression using a single imaging type alone (whether T2-weighted or post-contrast T1-
weighted MRI images or FET images) thereby increasing the chance of translation to the clinic. The importance 
of carefully crafting the clinical methodology in ML applications is highlighted in the CNN and FET studies 
described above, because the aim to differentiate progression and pseudoprogression was not truly addressed. 
This is because pseudoprogression and radiation necrosis (late-delayed radiation effects) are not interchangeable 
terms28. Although some researchers have interchangeably used the terms radiation necrosis and 
pseudoprogression33,34, this should be avoided as there are differences in the clinical and radiological course of 
the two entities28 and the histopathological and molecular phenotype differ35. The CNN study and the FET study 
included a mixture of cases of pseudoprogression and radiation necrosis.  
 
Over time: a longitudinal imaging series can be used to analyse pseudoprogression 
Dictionary learning has been employed to differentiate progression from pseudoprogression by performing 
implicit feature engineering without the need for tumour segmentation. In one glioblastoma study, features were 
estimated by using spatio-temporal discriminative dictionary learning of longitudinal diffusor tensor imaging 
(DTI) images to determine the sparse coefficients that were not shared between those with progression and 
pseudoprogression36. Then, after applying a score to each coefficient, a feature set was selected by sequentially 
adding the highest scoring coefficients using 10-fold cross validation and classifying the cases using an SVM. 
The best performance gave an accuracy of 0.87 and an AUC of 0.92. Again, it was unclear whether second line 
agents had been used, and there was no test dataset to validate the model. However, they were able to demonstrate 
some interpretability in that those with progression represented higher fractional anisotropy as might be expected 
due to the orientation of overproduced extracellular matrix in glioblastoma. Translation may be challenging 
because multiple concatenated DTI time points were required for the optimal classifier which might be logistically 
difficult to obtain in routine practice and again it is noteworthy that simple clinical features were not included. 
Combinations: multiple imaging types can be combined as a means to analyse pseudoprogression 
Traditional explicit feature engineering was used to differentiate progression from pseudoprogression within 3 
months following chemoradiation of glioblastoma using simple and first order 3D shape features37. Post-contrast 
T1-weighted and FLAIR images were combined, applying SVM and 4-fold cross validation. Sixty features were 
reduced to 5 and gave an accuracy of 0.9 in both a training dataset of 59 patients and a test dataset of 41 patients, 
which achieved 100% recall. Correlation coefficients comparing the most discriminant features at the two sites 
were high. The T2-weighted hyperintensity phenotype of those patients with progression compared to those with 
pseudoprogression was round rather than elliptic; the post-contrast T1-weighted phenotype was round and 
compact. As with the longitudinal DTI study, clinical data was not included in the analysis, and the results were 
not compared with simpler models, but the use of routine post-contrast T1-weighted and T2-weighted images 
increases the chance of translation.  
Old and new: long-established ML methods have been used with advanced imaging to analyse pseudoprogression 
As an alternative to SVM, a generalized linear model was applied to first order, second order and wavelet-
transformed imaging features to differentiate progression from pseudoprogression in glioblastoma38. Post-contrast 
T1-weighted, FLAIR, DSC and apparent diffusion coefficient (ADC) images were obtained within 3 months 
following chemoradiation from a training dataset of 61 patients. Feature selection by LASSO using 10-fold cross 
validation reduced the features from 6472 to 12. Classification using a generalized linear model showed that a 
multiparametric model of predominantly second order features (texture) gave an AUC of 0.90. Although relevant 
clinical and molecular data were collected, they were not included in any model despite MGMT promoter 
methylation status being shown to be significantly different in those with progression and pseudoprogression. The 
work was validated in a test dataset of 34 patients from a second hospital, although with a reduced AUC and 
accuracy, with some evidence of overfitting in the DSC component. This is likely to be associated with variation 
in how DSC is performed between centres39, and is one reason why multiparametric techniques are challenging 
to translate. 
Other long-established regression analyses within the definition of ML include multivariate logistic regression 
which has been employed in studies aiming to differentiate progression from pseudoprogression in glioblastoma40-
43. A multivariate logistic regression model (LRM) employing LOOCV was applied in a study using DTI and 
DSC metrics to differentiate tissue containing pseudoprogression from tissue containing progression within 6 
months following chemoradiation41. Using maximum relative cerebral blood volume (i.e. normalised to 
contralateral white matter; rCBV) and fractional anisotropy features obtained from the segmented enlarging 
contrast-enhancing lesions of 41 patients, the LRM gave an AUC of 0.81, recall of 0.79 and accuracy of 0.63.  
LRM with LOOCV was also applied to 33 patients using dynamic contrast-enhanced imaging (DCE) metrics 
acquired from the enlarging contrast-enhancing lesion within 2 months after chemoradiation42. Unlike the other 
neuro-oncology monitoring studies in this review, this study was an entirely prospective study. Key clinical 
predictors were analysed and shown not to be discriminative. There was good inter-observer reliability. Using 
mean Ktrans (the volume transfer constant is a measure of capillary permeability obtained using DCE which reflects 
the efflux rate of gadolinium contrast from blood plasma into the tissue extravascular extracellular space), the 
LRM gave an accuracy of 0.76 and recall of 0.59.  
In a further study of 35 patients, LRM was applied to subtracted ADC and DSC histograms of contrast-enhancing 
lesions obtained at baseline (around the time of chemoradiation) and at the point of enlargement within 6 months 
after chemoradiation40. Using the mode rCBV, LRM gave an AUC of 0.88, recall of 0.82 and accuracy of 0.94. 
In summary, long-established ML methods can be used with advanced imaging techniques such as DSC or DCE 
to differentiate progression and pseudoprogression. A strength of the LRM studies is that the results are 
interpretable as they relate to the increased perfusion (CBV) and permeability (Ktrans) occurring as a result of 
increased angiogenesis, the orientation of overproduced extracellular matrix (fractional anisotropy) and increased 
cellularity (ADC) known to be present in the enhancing rim of a glioblastoma. However, unlike in the generalized 
linear model approach, there were no test datasets employed in these single centre LRM studies. 
Clustered combinations: unsupervised analyses can also be applied to multiple imaging types to analyse either 
pseudoprogression or the broader group of treatment-related effects 
An unsupervised volume-weighted, voxel-based, multiparametric clustering method was used to differentiate 
progression from pseudoprogression within 3 months following chemoradiation44 as well as recurrence from 
radiation necrosis in enlarging contrast-enhancing lesions seen after 3 months45. Pseudoprogression can occur up 
to 6 months46, so the classifier in the second study is not examining radiation necrosis alone but two distinct 
entities combined35 (or “treatment-related effects”). In the first study, metrics from ADC, DSC and DCE 
underwent k-means clustering in a training dataset of 108 patients and a test dataset of 54 patients. AUC in the 
test dataset was > 0.94 and accuracy and recall was > 0.87 for each of two readers with reliability intra-class 
correlation coefficient of 0.89. In the second study, the same metrics were included although a necrosis cluster 
was added to the finalized clusters analysed in the previous study. Boot strapping with LOOCV and 5-fold cross 
validation were used for evaluation. AUC in the training dataset of 75 patients was > 0.94 and recall was > 0.95 
for each of two readers but there was no separate test dataset. As with many neuro-oncology monitoring biomarker 
studies, including the three studies using LRM above, it was unclear whether second line agents had been used 
which may confound the results. The results are impressive, particularly in the test dataset in the first study, 
however as with the LRM studies, multiparametric techniques are challenging to translate particularly with the 
known variation in advanced imaging techniques, including DCE, between centres39.  
Combinations and radiation necrosis: multiple imaging types can be combined as a means to analyse radiation 
necrosis 
A feasibility study to differentiate radiation necrosis and progression in enlarging contrast-enhancing lesions seen 
after 9 months of chemoradiation was performed for both glioblastoma and brain metastases using FLAIR, T2-
weighted and contrast-enhanced T1-weighted images47. There were 22 patients in a training dataset and 11 in a 
test dataset for glioblastoma patients and 21 in a training dataset and 4 in a test dataset for patients with brain 
metastases. Feature selection was performed with a feed-forward minimum redundancy and maximum relevance 
algorithm to reduce 119 features, including first and second order features as well as Laws and Laplacian pyramid 
features, to 5. Classification was performed by SVM recursive feature elimination with 3-fold cross validation. In 
the training datasets AUC was 0.79 for both tumour types using FLAIR images alone. In the test datasets, accuracy 
was 0.91 and 0.5 for glioblastoma and metastasis sub studies respectively, although all 3 MRI sequences were not 
available for all cases which makes interpretation challenging. The authors postulate that the features extracted in 
the study may relate to patterns similar to what is sometimes observed qualitatively in radiation necrosis, namely 
that the extracted Laws features relate to a soap-bubble appearance and that Laplacian pyramid features relate to 
an enhancing feathery rim. Furthermore, the Haralick features (second order texture features that are functions of 
the elements of the gray-level co-occurrence matrix and represent a specific relation between neighboring voxels) 
may relate to hypointensities and hyperintensities seen on all 3 MRI sequences due to microhaemorrhages in 
tumours. Because routine structural images were used, the chance of translation to the clinic is increased. Clinical 
data was not included in the analysis or models. 
Voxel-based approaches can be used in the analysis of treatment-related effects 
Proof-of-concept voxel-based approaches using ML to differentiate radiation necrosis and progression were 
developed in 2011 using DSC and ADC data48. In a recent study, whose aim was to differentiate progression from 
treatment-related effects (both pseudoprogression and radiation necrosis) in high grade glioma, a linear kernel 
SVM classifier was trained using DCE metrics (including Ktrans) of 10 voxels within the enlarging contrast-
enhancing lesion taken from 25 images from 20 patients49. Two-fold cross validation gave a recall of > 0.97. The 
model was applied to all voxels from a larger dataset of 44 images from the same 20 patients and shown to be 
interpretable and meaningful, including when there was a locally different treatment response in different lesions 
in the same patient. However, translation of the model may be challenging because it was trained on a small 
number of patients incorporating mixed grade, mixed treatment-effect (pseudoprogression and radiation necrosis), 
and mixed time points of the enlarging contrast-enhancing lesion (i.e. images not only from the first time point 
that an enlarging lesion is seen). There is also the potential for overfitting because images from several time points 
were used from the same patient to train the model.  
Analysis of complete response 
 
One study aimed to differentiate a complete response from progression a month before routine imaging 
assessment3,4 would detect this using data from two immunotherapy studies50. Immunotherapy was added to the 
standard of care in one study and as a second line therapy in another. First and second-order features were 
extracted from FLAIR, T2-weighted, contrast-enhanced T1-weighted images, and other metrics were obtained 
from DTI and DSC images. Feature selection was performed using several algorithms including minimum 
redundancy maximum relevance and random forest to reduce 1248 features to 10 or less features. Classification 
was also performed by a range of algorithms and these included SVMs, random forest, linear discriminant analysis 
and stochastic gradient boosting. LOOCV, which consisted of leaving one patient out as opposed to one image 
out as multiple images were used for each patient, was performed during feature selection and classification. The 
highest balanced accuracy came from features derived from contrast-enhanced T1-weighted and DSC images 
using a radial basis function SVM or boosting classifiers. However, no test dataset was used, and the methodology 
has significant weaknesses, in that it does not cater for a range of clinically-likely outcomes, such as stable disease.  
Prognostic Biomarkers 
Prognostic biomarkers identify the likelihood of a clinical event, recurrence, or progression based on the natural 
history of the disease1. They are generally associated with specific outcomes such as overall survival or 
progression-free survival. The potential for confounding in prognostic biomarker and monitoring biomarker 
studies overlaps. Both may be influenced by second line treatments and a range of clinical variables. Most studies 
leveraging ML (Table 2) are also performed in a single centre and are retrospective.  
 
Diagnostic biomarkers (described in detail in the other Special Issue publication dedicated to the application of 
machine learning in glioma imaging) may predict molecular information within a tumour from the imaging. 
Examples include MGMT promoter methylation status, 1p/19q chromosome arm co-deletion status and isocitrate 
dehydrogenase (IDH) mutation status. It is noteworthy that because some molecular markers are prognostic 
biomarkers in the same way that histopathological grade is a prognostic biomarker, diagnostic biomarkers may 
be prognostic biomarkers using the molecular marker or grade as a common biomarker. Another similarity of 
diagnostic and prognostic biomarker studies is that they both typically extract features from pre-operative MRIs 
and they often share methodology.  
 
Given the overlap in principles described here and in the adjoining publication, we describe just two instructive 
studies as examples. In one study, an ML algorithm aimed to determine overall survival using imaging features 
from pre-operative routine MRI in patients with glioblastoma51. Pre- and post-contrast T1-weighted, FLAIR, DSC 
and DTI images were obtained from a training dataset of 105 patients. Enhancing tumour tissue, non-enhancing 
tumour tissue, and oedematous tissue regions were segmented to produce imaging descriptors including location 
and first order statistics features and added to limited demographic features. Sixty features with the best survival 
prediction following 10-fold cross validation were selected from > 150 extracted features. Two SVMs were used 
to classify patients as survivors or not at 6 and 18 months respectively and a combined prediction index calculated. 
Ten-fold cross validation was used and gave an accuracy of 0.77 for predicting short, medium and long-term 
survivors. A prospective test dataset of 29 patients gave an accuracy of 0.79. Again, simple data such as 
performance status, which is known to be an important co-variate in multivariate analyses of glioma survival, 
were not included. To make the findings interpretable and meaningful, histograms were produced in order to 
understand the predictive features. Older patients, large tumour size, increased tumour diffusivity (potentially 
representing necrosis), larger proportions of T2 hypointensity within a region, and highest perfusion peak heights, 
were all predictive of short survival. Although the findings have a plausible biological basis, translation is limited 
as this was performed in a single centre. It is also noteworthy that the process of predicting survival at set time 
points (6 and 18 months) is generally less useful than producing estimates over time (as survival curves allow). 
 
An ML algorithm was used to determine overall survival of patients with high grade glioma using data from the 
brain tumor segmentation challenge (BRaTS)52. Pre- and post-contrast T1-weighted, T2-weighted and FLAIR 
images were obtained from a training dataset of 163 patients. Segmented regions including enhancing tumour 
tissue, non-enhancing tumour tissue, and oedematous tissue regions were manually segmented. Different sets of 
features were selected for classification. These included simple features such as location; histograms; discrete 
wavelet transform first and second order statistics; and a CNN which produced over 4000 deep features. The CNN 
was built using transfer learning based on AlexNet (a convolutional neural network that is trained on more than a 
million images from the ImageNet database53), and so benefits from the work already undertaken as part of the 
construction of an open source ‘off-the-shelf’ algorithm. Patients were classified as survivors or not at 10 and 15 
months respectively. SVMs, k-nearest neighbours, linear discriminant analysis, tree, ensemble, and logistic 
regression were all independently applied to each set of features. A combination of CNN deep features and a 
linear discriminant classifier with 5-fold cross validation gave the best predictive result, although the reduction in 
accuracy between the training and test dataset (0.99 to 0.55) provides clear evidence of overfitting. 
Predictive Biomarkers 
Predictive biomarkers identify individuals likely to experience a favourable or unfavourable effect from a specific 
intervention or exposure1. Therefore, a predictive biomarker requires an interaction between treatment and the 
biomarker. Biological subsets (such as MGMT promoter methylation status, 1p/19q chromosome arm co-deletion 
status and IDH mutation status) may correlate with a favourable or unfavourable effect and in these cases there is 
an overlap with diagnostic and prognostic biomarkers54. There are few truly predictive biomarkers in neuro-
oncology, molecular or otherwise. One study has applied unsupervised and supervised ML techniques to genomic 
information to predict whether pseudoprogression or true progression will occur after treatment55. Analytical and 
clinical validation in this radiogenomic study strongly suggested that interferon regulatory factor (IRF9) and X-
ray repair cross-complementing gene (XRCC1), which were involved in cancer suppression and prevention 
respectively, are predictive biomarkers.  
Conclusion 
ML applications to imaging in neuro-oncology are at an early stage of development and applied techniques are 
not ready to be incorporated into the clinic. Many ML studies would benefit from improvements to their 
methodology. Examples include the use of larger datasets, the use of external validation datasets and comparison 
of the novel approach to simpler standard approaches. Initiatives and consensus statements have provided 
recommended frameworks17,57,58 for standardizing imaging biomarker discovery, analytical validation and clinical 
validation which can help to improve the application of ML to neuro-oncology. 
 
Studies taking advantage of enhanced computational processing power to build neuro-oncology monitoring 
biomarker models, for example using CNNs, have yet to show benefit compared to ML techniques using explicit 
feature engineering and less computationally expensive classifiers, for example using multivariate logistic 
regression. It is also notable that studies applying ML to build neuro-oncology monitoring biomarker models have 
yet to show overall advantage over those using traditional statistical methods59,60. However, regardless of method, 
increased computational power and advances in database curation will facilitate integration of imaging data with 
demographic, clinical and molecular marker data.  
MRI is typically used throughout the neuro-oncology patient pathway however a major stumbling block of MRI 
is its flexibility. The same flexibility that makes MRI so powerful and versatile, also makes it hard to harmonise 
images from different centres. Afterall, MRI physics is complex and it is challenging (if not impossible) to fully 
harmonise parameters from different sequences, manufacturers and coils. These problems can be mitigated to 
some extent by manipulating the training dataset, such as through data augmentation, thereby allowing more 
generalisable ML models to be applied to MRI. Other approaches can describe the disharmony through modelling 
prediction uncertainty including the generation of algorithms that would "know when they don't know" what to 
predict. 
 
Development and validation of ML models applied to neuro-oncology require large, well-annotated datasets, and 
therefore multidisciplinary and multi-centre collaborations are necessary. Radiologists are critical in determining 
key clinical questions and shaping research studies that are clinically valid. When these models are ready for the 
clinic as a routine clinical tool, as with the application of any medical device or the introduction of any therapeutic 
agent, there needs to be judicious patient and imaging selection reflecting the cohort used for validation of the 
model.  
 
Alongside the drive towards clinical utility, the related issue of interpretability is likely to be important. As well 
as increasing user confidence, interpretability might help to generate new biological research hypotheses derived 
from image feature discovery.  
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Table 1. Recent studies applying machine learning to the development of neuro-oncology 
monitoring biomarkers 
 
Author(s) Prediction Dataset Method Results 
Cha J et al., 
201440 
True 
progression  
35 CBV & ADC Retrospective.  
Multivariate logistic 
regression, longitudinal 
subtraction of ADC & CBV 
histograms 
Mode of rCBV  
AUC - 0.877 
Park JE et al., 
201544 
Early true 
progression 
162 (training = 108 & 
testing = 54) DWI, DSC, 
DCE  
Retrospective.  
Volume-weighted, MP 
clustering 
Sensitivity - 87% 
Specificity - 87.1% 
AUC - 0.96 
Yun TJ et al., 
201542 
True 
progression 
33 DCE Prospective.  
Multivariate logistic 
regression, Ktrans, ve, vp 
Ktrans 
Accuracy - 76% 
Sensitivity - 59% 
Specificity - 94% 
Artzi M et al., 
201649 
Pseudo 
progression 
20 longitudinal patients 
DCE & MRS 
(training = 25/44 DCE & 
MRS studies; testing = 
19/44 studies) 
Prospective.  
Voxel-wise SVM with 
Ktrans, ve, Kep, vp. 
Sensitivity - 98% 
Specificity - 97% 
Tiwari P et 
al., 201647 
Radiation 
necrosis 
58 (training = 43 & 
testing = 15) MRI  
Retrospective.  
119 features, mRmR feature 
selection, SVM. Sequence 
independent. 
AUC - 0.79 
AUC (primary) -
0.77 
AUC (metastatic) - 
0.72 
Qian X et al., 
201636 
True 
progression 
35 longitudinal DTI Retrospective.  
Spatio-temporal dictionary 
learning & SVM 
classification 
Accuracy - 86.7% 
AUC - 0.92 
Ion-
Margineanu 
A et al., 
201650 
 
True 
progression 
29 T1, T1 C, DKI, DSC Prospective.  
Compared 7 classifiers over 
various global and local 
features. 
T1 C 
Max BAR 
(balanced accuracy 
rate) value - 0.96 
for AdaBoost 
Yoon RG et 
al., 201745 
True 
progression 
75 MRI, DWI, DSC, DCE Retrospective. 
Unsupervised.  
MP clustering of ADC, 
rCBV, IAUC 
Sensitivity - 96.4% 
Specificity - 81.8% 
AUC - 0.95 
Booth TC et 
al., 201712 
True 
progression 
50 feature estimation.  
24 (training = 17 & 
testing = 7) T2 
Prospective testing set. 
SVM using Minkowski 
functionals 
Accuracy - 88% 
AUC - 0.9 
Kebir S et al., 
201730 
True 
progression 
14 18F-FET-PET Retrospective. 
Unsupervised. Consensus 
Sensitivity - 90% 
Specificity - 75% 
clustering, 19 conventional 
and textural features 
NPV - 75% 
Nam JG et al., 
201743 
True 
progression 
37 DCE  Retrospective.  
Multivariate logistic 
regression using 
pharmacokinetic parameters 
Kep  
Accuracy - 70.3% 
AUC - 0.75 
Sensitivity - 71.4% 
Specificity - 90.0% 
Jang B-S et 
al., 201831 
Pseudo 
progression 
78 (training = 59 & 
testing = 19) T1 C MRI, 
Age, Gender, MGMT 
status, IDH mutation, 
radiotherapy dose & 
fractions, follow up 
interval 
Retrospective.  
9 T1 C axial slices centred 
on lesion, CNN 
AUC - 0.83  
AUPRC - 0.87 
F1 score- 0.74 
 
Ismail M et 
al., 201837 
True 
progression 
105 (training = 59 & 
testing = 46)  MRI 
Retrospective.  
SVM using global & local 
features of lesion & 
peritumour habitat 
Accuracy - 90.2% 
Sensitivity - 100% 
Specificity - 94.7% 
Kim JY et al., 
201838 
Early true 
progression 
95 (training = 61 & 
testing = 34) T1 C, 
FLAIR, DWI, DSC 
Retrospective.  
Generalised linear model, 
LASSO feature selection on 
multiparametric first- & 
second-order statistics. 
AUC - 0.85 
Sensitivity - 71.4% 
Specificity - 90.0% 
18F-FET-PET = [18F]-fluoroethyl-L-tyrosine positron emission tomography. NPV = negative predictive value. T1 C = post contrast T1-
weighted. MGMT = O6-methylguanine-DNA methyltransferase. IDH = isocitrate dehydrogenase. CNN = convolutional neural network. AUC 
= area under the receiver operator curve. AUPRC = area under the precision-recall curve. DCE = dynamic contrast-enhanced imaging. MRS 
= 1H-magnetic resonance spectroscopy. SVM = support vector machine. mRmR = minimum redundancy and maximum relevance. CBV = 
cerebral blood volume (rCBV =relative CBV). ADC = apparent diffusion coefficient. IAUC = initial area under the curve. MP =multi 
parametric. DWI = diffusion weighted imaging. DSC = dynamic susceptibility-weighted. LASSO = least absolute shrinkage and selection 
operator. DTI = diffusor tensor imaging. DKI = diffusor kurtosis imaging. 
 
 
Table 2. Recent studies applying machine learning to the development of neuro-oncology 
prognostic biomarkers 
 
Author(s) Dataset Method Results 
Choi YS et al., 
201561 
61 preoperative DCE Retrospective.  
Multivariate Cox regression using 
MRI, pharmacokinetic, & clinical 
parameters 
C-index - 0.82 
Kickingereder P et 
al., 201662 
119 (training = 79 & 
testing = 40) T1, T1 C, 
FLAIR, DWI, DSC 
 
Retrospective.  
Supervised Principal Component 
Analysis with Cox regression 
analysis 
C-index - 0.70 
Chang K et al., 
201663 
126 (training = 84 & 
testing = 42) patients T1, 
T2, FLAIR, T1 C, DWI 
Retrospective.  
Random forest on radiomic features 
(including Laws, Haralick) 
Accuracy - 76% 
Liu L et al, 201664 147 rs-fMRI and DTI Retrospective.  
SVM using clinical features & 
network features of structural & 
functional network 
Accuracy - 75% 
Nie D et al, 201665 69 T1 C, rs-fMRI, DTI Prospective.  
SVM using supervised CNN-derived 
features 
Accuracy - 89.9% 
Sensitivity - 96.9% 
Specificity - 83.8% 
PPR - 84.9% 
NPR - 93.9% 
Macyszyn L et al., 
201651 
134 (training = 105 & 
testing = 29) T1, T1 C, 
T2, FLAIR, DTI, DSC 
Prospective.  
SVM  for OS < 6 months & SVM for 
OS < 18 months 
Accuracy (< 6 months) - 
82.76% 
Accuracy (< 18 months) 
- 83.33% 
Accuracy (combined) - 
79% 
Zhou M et al., 
201766 
32 TCGA T1 C, FLAIR, 
T2 & 
22 T1 C, FLAIR, T2 
Retrospective.  
Group Difference Features to 
quantify habitat variation. Supervised 
forward feature ranking with SVM. 
Accuracy - 87.5%, 
86.4% 
 
Dehkordi ANV et 
al., 201767 
33 pre-treatment DCE 
 
Retrospective.  
Adaptive Neural Network with Fuzzy 
Inference System using Ktrans, Kep and 
ve 
Accuracy - 84.8% 
Lao J et al., 201768 112 (training = 75 & 
testing = 37) pre-
treatment T1, T1 C, T2, 
FLAIR 
Retrospective.  
Multivariate Cox regression analysis 
using radiomic features as well as 
‘deep features’ from pre-trained 
CNN. 
C-index - 0.71 
Liu Y et al., 201769 133 T1 C  
 
 
Retrospective.  
Recursive Feature Selection with 
SVM 
 
Accuracy - 78.2%  
AUC - 0.81 
Sensitivity -  79.1% 
Specificity - 77.3% 
Li Q et al., 201770 92 (training = 60, 
testing = 32) T1, T1 C, 
T2, FLAIR. 
TCGA data used. 
Retrospective.  
Random forest for segmentation into 
5 classes. Multivariate LASSO-Cox 
regression model. 
C-index - 0.71 
 
Chato L & Latifi 
S, 201752 
163 T1, T1 C, T2, FLAIR. 
Short-, mid-, long-term 
survivors 
Retrospective.  
SVM, KNN, linear discriminant, tree, 
ensemble & logistic regression 
applied to 
volumetric, statistical & intensity 
texture, histograms & deep features. 
Accuracy - 91% 
Linear discriminant 
using deep features 
Ingrisch M et al., 
201771 
66 T1 C Retrospective.  
Random survival forests using 208 
global & local features from 
segmented tumour 
C-index - 0.67 
Li Z-C et al., 
201772 
92 (training = 60 & 
testing = 32) T1, T1 C, 
T2, FLAIR. 
TCGA data used. 
Retrospective.  
LASSO Cox regression to define 
radiomics signature 
C-index - 0.71 
 
Bharath K et al., 
201773 
63 TCGA preoperative - 
T1 C, FLAIR 
Retrospective.  
LASSO Cox regression using Age, 
KPS, DDIT3 & 11 Principal 
Component shape coefficients 
C-index - 0.86 
Z Shboul et al., 
201774 
163 T1, T1 C, T2, FLAIR Retrospective.  
Recursive feature selection & 
Random Forest regression. 
Accuracy – 63% 
Peeken JC et al., 
201875 
189 T1, T1 C, T2, FLAIR 
& clinical data. 
Retrospective.  
Multivariate Cox regression using 
VASARI features and clinical data  
C-index - 0.69 
P Kickingereder et 
al., 201876 
181 (training = 120 & 
testing = 61) 
pretreatment MRI 
Retrospective.  
Penalized Cox model for radiomic 
signature construction.  
C-index – 0.77 
A Chaddad et al., 
201877 
40 (training = 20 & 
testing = 20) 
preoperative MRI, T1 & 
FLAIR. 
Retrospective.  
Random Forest on multi-scale texture 
features 
AUC – 74.4% 
S Bae et al., 201878 217 (training = 163 & 
testing = 54) pre-
Retrospective.  
Variable hunting algorithm for 
selection & Random Forest classifier 
iAUC - 0.65 
 
operative MRI, T1 C, 
T2,, FLAIR, DWI 
TCGA = The Cancer Genome Atlas . T1 C = post contrast T1 -weighted. SVM = support vector machine. DCE = dynamic contrast-enhanced 
imaging. CNN = convolutional neural network. KNN = k-nearest neighbours/ rs-fMRI = resting state functional MRI. KPS = Karnofsky 
performance status. DDIT3 = DNA Damage Inducible Transcript 3. DTI = diffusor tensor imaging. DSC = dynamic susceptibility-weighted. 
OS = overall survival 
 
 
 
Figure 1. The phases of radiomics are shown using explicit feature engineering. Some pre-
processing steps are shown here: manual segmentation of hyperintense voxels associated with 
a glioblastoma in a T2-weighted image is performed. A mask is extracted which undergoes 
quantization. Some feature estimation steps are shown here: in this example, the pixels are 
made into three features which are topological descriptors of image heterogeneity12 (area is the 
number of white pixels = 1; perimeter around a white pixel = 4; genus is the number of rings 
subtracted from number of holes = 0). Note that deep learning uses implicit feature engineering 
and some of the feature estimation steps may not be required. 
 
Figure 2. A longitudinal series of T1-weighted images after gadolinium administration. On 
the left is an image demonstrating a glioblastoma 1 month after surgery before 
chemoradiotherapy. In the middle is an image demonstrating the appearances 2 months after 
radiotherapy and concomitant chemotherapy. On the right is an image demonstrating the 
appearances 4 months after radiotherapy and concomitant chemotherapy. There was no new 
treatment between 2 and 4 months therefore this shows pseudoprogression occurred at 2 
months.  
 
